So far, CTLA4 (cytotoxic T-lymphocyte protein 4; Ipilimumab) and PD-1 (programmed cell death 1; Nivolumab, Pembrolizumab) axis targeting immune checkpoint inhibitors have been approved for the treatment of metastatic melanoma. Here, CTLA4 is linked to metastatic melanoma.